Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European ...

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001) All secondary efficacy endpoints met (p<0.0001), including End of ...

Ionis IONS and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema ...

Good day and thank you for standing by. Welcome to the RAPIDe-3 topline data webcast. [Operator Instructions] I would now like to hand the conference over to your speaker, Maggie, please go ahead.

Interim results from KONFIDENT-KID show sebetralstat enables early, effective, safe treatment of HAE attacks in pediatric population and reveal higher attack frequency than previously believed ...

The goal of acute treatment of an hereditary angioedema (HAE) attack is to reduce its duration and severity and thus limit its impact on the patient’s functional ability and prevent a potentially ...

Optimal care for female and pediatric patients with hereditary angioedema (HAE) requires consideration of several population-specific issues. For women, these include menstruation, contraception, ...

Ionis Pharma & Otsuka’s donidalorsen gets approval in European Union for hereditary angioedema: Carlsbad, California Saturday, January 24, 2026, 13:00 Hrs [IST] Ionis Pharmaceut ...